These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 27984634)
1. Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment? Falchi L; Bose P; Newberry KJ; Verstovsek S Br J Haematol; 2017 Feb; 176(3):352-364. PubMed ID: 27984634 [TBL] [Abstract][Full Text] [Related]
2. Target hematologic values in the management of essential thrombocythemia and polycythemia vera. Hernández-Boluda JC; Gómez M Eur J Haematol; 2015 Jan; 94(1):4-11. PubMed ID: 24814134 [TBL] [Abstract][Full Text] [Related]
3. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Michiels JJ; Berneman ZN; Schroyens W; Van Vliet HH Platelets; 2004 Mar; 15(2):67-84. PubMed ID: 15154599 [TBL] [Abstract][Full Text] [Related]
4. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Elliott MA; Tefferi A Br J Haematol; 2005 Feb; 128(3):275-90. PubMed ID: 15667529 [TBL] [Abstract][Full Text] [Related]
5. Anagrelide: a review of its use in the management of essential thrombocythaemia. Wagstaff AJ; Keating GM Drugs; 2006; 66(1):111-31. PubMed ID: 16398570 [TBL] [Abstract][Full Text] [Related]
7. No treatment for low-risk thrombocythaemia: results from a prospective study. Ruggeri M; Finazzi G; Tosetto A; Riva S; Rodeghiero F; Barbui T Br J Haematol; 1998 Dec; 103(3):772-7. PubMed ID: 9858229 [TBL] [Abstract][Full Text] [Related]
8. Management of essential thrombocythemia. Cervantes F Hematology Am Soc Hematol Educ Program; 2011; 2011():215-21. PubMed ID: 22160037 [TBL] [Abstract][Full Text] [Related]
9. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274 [TBL] [Abstract][Full Text] [Related]
11. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia. Radaelli F; Colombi M; Calori R; Zilioli VR; Bramanti S; Iurlo A; Zanella A Hematol Oncol; 2007 Sep; 25(3):115-20. PubMed ID: 17464935 [TBL] [Abstract][Full Text] [Related]
12. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. Godfrey AL; Campbell PJ; MacLean C; Buck G; Cook J; Temple J; Wilkins BS; Wheatley K; Nangalia J; Grinfeld J; McMullin MF; Forsyth C; Kiladjian JJ; Green AR; Harrison CN; ; ; ; J Clin Oncol; 2018 Dec; 36(34):3361-3369. PubMed ID: 30153096 [TBL] [Abstract][Full Text] [Related]
13. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC Hematology; 2008 Apr; 13(2):71-6. PubMed ID: 18616871 [TBL] [Abstract][Full Text] [Related]
14. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. Tefferi A Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120 [TBL] [Abstract][Full Text] [Related]
15. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Campbell PJ; MacLean C; Beer PA; Buck G; Wheatley K; Kiladjian JJ; Forsyth C; Harrison CN; Green AR Blood; 2012 Aug; 120(7):1409-11. PubMed ID: 22709688 [TBL] [Abstract][Full Text] [Related]
16. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Carobbio A; Finazzi G; Antonioli E; Guglielmelli P; Vannucchi AM; Delaini F; Guerini V; Ruggeri M; Rodeghiero F; Rambaldi A; Barbui T Blood; 2008 Oct; 112(8):3135-7. PubMed ID: 18587010 [TBL] [Abstract][Full Text] [Related]
17. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations]. Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861 [TBL] [Abstract][Full Text] [Related]
18. Predictive factors of thrombosis for patients with essential thrombocythaemia: A single center study. Prajs I; Kuliczkowski K Adv Clin Exp Med; 2017; 26(1):115-121. PubMed ID: 28397442 [TBL] [Abstract][Full Text] [Related]
19. Prediction of major bleeding events in 1381 patients with essential thrombocythemia. Stuckey R; Ianotto JC; Santoro M; Czyż A; Encinas MMP; Gómez-Casares MT; Pereira MSN; de Nałęcz AK; Gołos A; Lewandowski K; Szukalski Ł; González-Martín JM; Sobas MA Int J Hematol; 2023 Nov; 118(5):589-595. PubMed ID: 37660316 [TBL] [Abstract][Full Text] [Related]
20. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Tefferi A Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]